NO20050083L - Ghrelin analoger - Google Patents

Ghrelin analoger

Info

Publication number
NO20050083L
NO20050083L NO20050083A NO20050083A NO20050083L NO 20050083 L NO20050083 L NO 20050083L NO 20050083 A NO20050083 A NO 20050083A NO 20050083 A NO20050083 A NO 20050083A NO 20050083 L NO20050083 L NO 20050083L
Authority
NO
Norway
Prior art keywords
ghrelin analogues
ghrelin
analogues
therapeutic
agonist
Prior art date
Application number
NO20050083A
Other languages
English (en)
Other versions
NO334857B1 (no
Inventor
Zheng Xin Dong
Yeelana Shen
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20050083L publication Critical patent/NO20050083L/no
Publication of NO334857B1 publication Critical patent/NO334857B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)

Abstract

Oppfinnelsen omfatter peptidyl-analoger som har agonist eller antagonist ghrelin aktivitet, sammen med terapeutiske og ikke-terapeutiske anvendelser derav.
NO20050083A 2002-07-23 2005-01-06 Ghrelin analoger samt anvendelse derav og fremgangsmåte for identifisering av en forbindelse som kan bindes til en GHS reseptor NO334857B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39783402P 2002-07-23 2002-07-23
US42748802P 2002-11-19 2002-11-19
PCT/US2003/022925 WO2004009616A2 (en) 2002-07-23 2003-07-23 Ghrelin analogs

Publications (2)

Publication Number Publication Date
NO20050083L true NO20050083L (no) 2005-03-23
NO334857B1 NO334857B1 (no) 2014-06-23

Family

ID=34278194

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050083A NO334857B1 (no) 2002-07-23 2005-01-06 Ghrelin analoger samt anvendelse derav og fremgangsmåte for identifisering av en forbindelse som kan bindes til en GHS reseptor

Country Status (18)

Country Link
US (3) US7589058B2 (no)
EP (2) EP1578778B1 (no)
JP (2) JP2006515271A (no)
KR (1) KR101065471B1 (no)
AR (2) AR040955A1 (no)
AT (1) ATE496940T1 (no)
AU (1) AU2003254119B2 (no)
BR (1) BR0312871A (no)
CA (1) CA2491946C (no)
DE (1) DE60335913D1 (no)
IL (1) IL166170A (no)
MX (1) MXPA05000908A (no)
NO (1) NO334857B1 (no)
PL (1) PL212106B1 (no)
PT (1) PT1578778E (no)
RU (3) RU2373220C2 (no)
TW (1) TWI325003B (no)
WO (1) WO2004009616A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101065471B1 (ko) 2002-07-23 2011-09-16 입센 파마 에스.에이.에스 그렐린 유사체
KR20070050871A (ko) * 2004-05-11 2007-05-16 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 그렐린을 사용하여 전염증성 사이토킨 발현을 억제하는방법
CN105111302A (zh) * 2005-09-28 2015-12-02 益普生制药股份有限公司 生长素释放肽类似物
WO2007041278A2 (en) * 2005-09-29 2007-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition and methods for stimulating gastrointestinal motility
US8992928B2 (en) * 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
US20100227806A1 (en) * 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
CA2645844C (en) * 2006-03-13 2016-04-26 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
BRPI0717169C1 (pt) * 2006-09-27 2012-12-04 Ipsen Pharma Sas análogos de grelina substituìda no n-terminal
WO2008067831A2 (en) * 2006-12-05 2008-06-12 Charite Universitätsmedizin - Berlin Use of ghrelin, an analogue thereof or a pharmaceutically acceptable salt thereof
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
CA2761901C (en) * 2009-05-12 2019-08-13 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2011053821A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
AU2011268256B8 (en) * 2010-06-16 2016-12-22 Mcgill University Growth hormone secretatogue receptor antagonists and uses thereof
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
EP2809339A2 (en) * 2012-02-03 2014-12-10 Zealand Pharma A/S Ghrelin analogues
CA3062003C (en) 2012-05-17 2022-01-11 Extend Biosciences, Inc. Vitamin d as a targeting group for therapeutic peptides
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN108029863B (zh) * 2018-01-19 2021-07-27 广州英赛特生物技术有限公司 丁酰甘氨酸及其衍生物在制备动物饲料添加剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8821785D0 (en) * 1988-09-16 1988-10-19 Nycomed As Peptide compounds
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
CA2200606A1 (en) 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
WO1997021730A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
EP1992641A3 (en) * 1998-12-07 2009-07-29 Ipsen Pharma GLP-1 analogues
CN100506844C (zh) 1999-07-23 2009-07-01 寒川贤治 新的肽
JP2004514651A (ja) * 2000-05-30 2004-05-20 メルク　エンド　カムパニー　インコーポレーテッド グレリン類似体
JP2004504406A (ja) 2000-07-24 2004-02-12 アーダナ　バイオサイエンス　リミテッド グレリンアンタゴニスト
ATE512216T1 (de) 2001-04-10 2011-06-15 Agensys Inc Nukleinsäure und dieser entsprechendes, 184p1e2 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
KR101065471B1 (ko) 2002-07-23 2011-09-16 입센 파마 에스.에이.에스 그렐린 유사체

Also Published As

Publication number Publication date
CA2491946A1 (en) 2004-01-29
IL166170A0 (en) 2006-01-15
BR0312871A (pt) 2007-07-10
US8633151B2 (en) 2014-01-21
US20050272648A1 (en) 2005-12-08
IL166170A (en) 2011-01-31
RU2007124275A (ru) 2009-01-10
US20140135260A1 (en) 2014-05-15
PT1578778E (pt) 2011-03-07
US9133261B2 (en) 2015-09-15
RU2315059C2 (ru) 2008-01-20
RU2009127162A (ru) 2011-01-20
AU2003254119B2 (en) 2007-11-29
TW200403253A (en) 2004-03-01
EP2258381A3 (en) 2011-11-02
PL212106B1 (pl) 2012-08-31
EP2258381A2 (en) 2010-12-08
EP1578778A4 (en) 2007-02-28
AR073099A2 (es) 2010-10-13
WO2004009616A3 (en) 2006-02-09
MXPA05000908A (es) 2005-07-22
RU2005104841A (ru) 2005-09-10
RU2373220C2 (ru) 2009-11-20
EP1578778A2 (en) 2005-09-28
AR040955A1 (es) 2005-04-27
EP1578778B1 (en) 2011-01-26
JP2009161546A (ja) 2009-07-23
NO334857B1 (no) 2014-06-23
DE60335913D1 (de) 2011-03-10
KR101065471B1 (ko) 2011-09-16
ATE496940T1 (de) 2011-02-15
US7589058B2 (en) 2009-09-15
PL377075A1 (pl) 2006-01-23
WO2004009616A2 (en) 2004-01-29
AU2003254119A1 (en) 2004-02-09
JP2006515271A (ja) 2006-05-25
US20100069299A1 (en) 2010-03-18
CA2491946C (en) 2013-05-28
KR20050026503A (ko) 2005-03-15
TWI325003B (en) 2010-05-21

Similar Documents

Publication Publication Date Title
NO20050083L (no) Ghrelin analoger
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
DK1501815T3 (da) Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
NO20052739D0 (no) CCR5-antagonister som medikamenter
DK1997810T3 (da) Indazoler, benzotriazoler og N-analoger deraf som p38-kinaseinhibitorer
DK1401806T3 (da) Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler
NL1023157A1 (nl) Stabilisatormengsels.
FI20022225A0 (fi) Sykerajan asettaminen sykemittarissa
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
DK1511764T3 (da) Peptider og peptidomimetika, som er egnede til hæmning af aktiviteten af prostaglandin f2alfa-receptor
ITMI20022022A1 (it) Analoghi di nocicettina.
ITTO20020117A0 (it) Apparecchiatura per prove tribologiche.
ITMO20020337A1 (it) Dispositivo per anastomosi.
ITMI20030897A1 (it) Procedimento e apparecchiatura per frazionare sangue.
ATE404602T1 (de) Wässrige polyurethanzubereitungen
NO20053598D0 (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
ITMI20030095A1 (it) Procedimento e dispositivo per comandare o regolare un compressore.
BRPI0417265A (pt) composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
AU2003222462A1 (en) Method of performing soojichim acupuncture using bodycopy
DK1572653T3 (da) Mættede og umættede heteroarylcycloalkylmethylaminer som antidepressiva
ES1052628Y (es) Extintor instantaneo.
ES1052073Y (es) Urna desmontable.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees